1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2. MARKET SNAPSHOT, 2022-2030 MILLION USD
2.1. MARKET SNAPSHOT
3. PORTER’S FIVE FORCE MODEL ANALYSIS
4. MARKET DYNAMICS
4.1. GROWTH DRIVERS
4.1.1 DRIVER 1
4.1.2 DRIVER 2
4.1.3 DRIVER 3
4.1.4 DRIVER 4
4.2. CHALLENGES
4.2.1 CHALLENGE 1
4.2.2 CHALLENGE 2
4.3. OPPORTUNITIES
4.3.1 OPPORTUNITY 1
4.3.2 OPPORTUNITY 2
5. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY
5.1. OVERVIEW
5.2. GENE INDUCED IMMUNOTHERAPY
5.2.1 GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
5.2.1.1 ADENOVIRUS MARKET, BY REGION
5.2.1.1.1 NORTH AMERICA ADENOVIRUS MARKET, BY COUNTRY
5.2.1.1.2 EUROPE ADENOVIRUS MARKET, BY COUNTRY
5.2.1.1.3 ASIA-PACIFIC ADENOVIRUS MARKET, BY COUNTRY
5.2.1.1.4 REST OF WORLD ADENOVIRUS MARKET, BY COUNTRY
5.2.1.2 LENTIVIRUS MARKET, BY REGION
5.2.1.2.1 NORTH AMERICA LENTIVIRUS MARKET, BY COUNTRY
5.2.1.2.2 EUROPE LENTIVIRUS MARKET, BY COUNTRY
5.2.1.2.3 ASIA-PACIFIC LENTIVIRUS MARKET, BY COUNTRY
5.2.1.2.4 REST OF WORLD LENTIVIRUS MARKET, BY COUNTRY
5.2.1.3 RETRO VIRUS MARKET, BY REGION
5.2.1.3.1 NORTH AMERICA RETRO VIRUS MARKET, BY COUNTRY
5.2.1.3.2 EUROPE RETRO VIRUS MARKET, BY COUNTRY
5.2.1.3.3 ASIA-PACIFIC RETRO VIRUS MARKET, BY COUNTRY
5.2.1.3.4 REST OF WORLD RETRO VIRUS MARKET, BY COUNTRY
5.2.1.4 ADENO ASSOCIATED VIRUS MARKET, BY REGION
5.2.1.4.1 NORTH AMERICA ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY
5.2.1.4.2 EUROPE ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY
5.2.1.4.3 ASIA-PACIFIC ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY
5.2.1.4.4 REST OF WORLD ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY
5.2.1.5 HERPES SIMPLEX VIRUS MARKET, BY REGION
5.2.1.5.1 NORTH AMERICA HERPES SIMPLEX VIRUS MARKET, BY COUNTRY
5.2.1.5.2 EUROPE HERPES SIMPLEX VIRUS MARKET, BY COUNTRY
5.2.1.5.3 ASIA-PACIFIC HERPES SIMPLEX VIRUS MARKET, BY COUNTRY
5.2.1.5.4 REST OF WORLD HERPES SIMPLEX VIRUS MARKET, BY COUNTRY
5.2.1.6 ALPHA VIRUS MARKET, BY REGION
5.2.1.6.1 NORTH AMERICA ALPHA VIRUS MARKET, BY COUNTRY
5.2.1.6.2 EUROPE ALPHA VIRUS MARKET, BY COUNTRY
5.2.1.6.3 ASIA-PACIFIC ALPHA VIRUS MARKET, BY COUNTRY
5.2.1.6.4 REST OF WORLD ALPHA VIRUS MARKET, BY COUNTRY
5.2.1.7 VACCINIA VIRUS MARKET, BY REGION
5.2.1.7.1 NORTH AMERICA VACCINIA VIRUS MARKET, BY COUNTRY
5.2.1.7.2 EUROPE VACCINIA VIRUS MARKET, BY COUNTRY
5.2.1.7.3 ASIA-PACIFIC VACCINIA VIRUS MARKET, BY COUNTRY
5.2.1.7.4 REST OF WORLD VACCINIA VIRUS MARKET, BY COUNTRY
5.2.1.8 SIMIAN VIRUS MARKET, BY REGION
5.2.1.8.1 NORTH AMERICA SIMIAN VIRUS MARKET, BY COUNTRY
5.2.1.8.2 EUROPE SIMIAN VIRUS MARKET, BY COUNTRY
5.2.1.8.3 ASIA-PACIFIC SIMIAN VIRUS MARKET, BY COUNTRY
5.2.1.8.4 REST OF WORLD SIMIAN VIRUS MARKET, BY COUNTRY
5.2.1.9 OTHERS MARKET, BY REGION
5.2.1.9.1 NORTH AMERICA OTHERS MARKET, BY COUNTRY
5.2.1.9.2 EUROPE OTHERS MARKET, BY COUNTRY
5.2.1.9.3 ASIA-PACIFIC OTHERS MARKET, BY COUNTRY
5.2.1.9.4 REST OF WORLD OTHERS MARKET, BY COUNTRY
5.2.2 GENE INDUCED IMMUNOTHERAPY MARKET, BY REGION
5.2.2.1 NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY
5.2.2.2 EUROPE GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY
5.2.2.3 ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY
5.2.2.4 REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY
5.3. ONCOLYTIC VIROTHERAPY
5.3.1 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
5.3.1.1 DELIVERY OF CYTOKINES GENE MARKET, BY REGION
5.3.1.1.1 NORTH AMERICA DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY
5.3.1.1.2 EUROPE DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY
5.3.1.1.3 ASIA-PACIFIC DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY
5.3.1.1.4 REST OF WORLD DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY
5.3.1.2 DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY REGION
5.3.1.2.1 NORTH AMERICA DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY
5.3.1.2.2 EUROPE DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY
5.3.1.2.3 ASIA-PACIFIC DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY
5.3.1.2.4 REST OF WORLD DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY
5.3.2 ONCOLYTIC VIROTHERAPY MARKET, BY REGION
5.3.2.1 NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY
5.3.2.2 EUROPE ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY
5.3.2.3 ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY
5.3.2.4 REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY
5.4. GENE TRANSFER
5.4.1 GLOBAL GENE TRANSFER MARKET, BY THERAPY
5.4.1.1 ELECTROPORATION MARKET, BY REGION
5.4.1.1.1 NORTH AMERICA ELECTROPORATION MARKET, BY COUNTRY
5.4.1.1.2 EUROPE ELECTROPORATION MARKET, BY COUNTRY
5.4.1.1.3 ASIA-PACIFIC ELECTROPORATION MARKET, BY COUNTRY
5.4.1.1.4 REST OF WORLD ELECTROPORATION MARKET, BY COUNTRY
5.4.1.2 SONOPORTION MARKET, BY REGION
5.4.1.2.1 NORTH AMERICA SONOPORTION MARKET, BY COUNTRY
5.4.1.2.2 EUROPE SONOPORTION MARKET, BY COUNTRY
5.4.1.2.3 ASIA-PACIFIC SONOPORTION MARKET, BY COUNTRY
5.4.1.2.4 REST OF WORLD SONOPORTION MARKET, BY COUNTRY
5.4.1.3 MAGNETOFECTION MARKET, BY REGION
5.4.1.3.1 NORTH AMERICA MAGNETOFECTION MARKET, BY COUNTRY
5.4.1.3.2 EUROPE MAGNETOFECTION MARKET, BY COUNTRY
5.4.1.3.3 ASIA-PACIFIC MAGNETOFECTION MARKET, BY COUNTRY
5.4.1.3.4 REST OF WORLD MAGNETOFECTION MARKET, BY COUNTRY
5.4.1.4 GENE GUN MARKET, BY REGION
5.4.1.4.1 NORTH AMERICA GENE GUN MARKET, BY COUNTRY
5.4.1.4.2 EUROPE GENE GUN MARKET, BY COUNTRY
5.4.1.4.3 ASIA-PACIFIC GENE GUN MARKET, BY COUNTRY
5.4.1.4.4 REST OF WORLD GENE GUN MARKET, BY COUNTRY
5.4.2 GENE TRANSFER MARKET, BY REGION
5.4.2.1 NORTH AMERICA GENE TRANSFER MARKET, BY COUNTRY
5.4.2.2 EUROPE GENE TRANSFER MARKET, BY COUNTRY
5.4.2.3 ASIA-PACIFIC GENE TRANSFER MARKET, BY COUNTRY
5.4.2.4 REST OF WORLD GENE TRANSFER MARKET, BY COUNTRY
6. GLOBAL CANCER GENE THERAPY MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1 NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY
6.2.1.1 NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.2.1.2 NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.2.1.3 NORTH AMERICA GENE TRANSFER MARKET, BY THERAPY
6.2.2 NORTH AMERICA CANCER GENE THERAPY, MARKET BY COUNTRY
6.2.2.1 U.S
6.2.2.1.1 U.S CANCER GENE THERAPY MARKET, BY THERAPY
6.2.2.1.1.1. U.S GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.2.2.1.1.2. U.S ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.2.2.1.1.3. U.S GENE TRANSFER MARKET, BY THERAPY
6.2.2.2 CANADA
6.2.2.2.1 CANADA CANCER GENE THERAPY MARKET, BY THERAPY
6.2.2.2.1.1. CANADA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.2.2.2.1.2. CANADA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.2.2.2.1.3. CANADA GENE TRANSFER MARKET, BY THERAPY
6.2.2.3 MEXICO
6.2.2.3.1 MEXICO CANCER GENE THERAPY MARKET, BY THERAPY
6.2.2.3.1.1. MEXICO GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.2.2.3.1.2. MEXICO ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.2.2.3.1.3. MEXICO GENE TRANSFER MARKET, BY THERAPY
6.3. EUROPE
6.3.1 EUROPE CANCER GENE THERAPY MARKET, BY THERAPY
6.3.1.1 EUROPE GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.1.2 EUROPE ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.1.3 EUROPE GENE TRANSFER MARKET, BY THERAPY
6.3.2 EUROPE CANCER GENE THERAPY, MARKET BY COUNTRY
6.3.2.1 GERMANY
6.3.2.1.1 GERMANY CANCER GENE THERAPY MARKET, BY THERAPY
6.3.2.1.1.1. GERMANY GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.2.1.1.2. GERMANY ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.2.1.1.3. GERMANY GENE TRANSFER MARKET, BY THERAPY
6.3.2.2 FRANCE
6.3.2.2.1 FRANCE CANCER GENE THERAPY MARKET, BY THERAPY
6.3.2.2.1.1. FRANCE GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.2.2.1.2. FRANCE ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.2.2.1.3. FRANCE GENE TRANSFER MARKET, BY THERAPY
6.3.2.3 UK
6.3.2.3.1 UK CANCER GENE THERAPY MARKET, BY THERAPY
6.3.2.3.1.1. UK GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.2.3.1.2. UK ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.2.3.1.3. UK GENE TRANSFER MARKET, BY THERAPY
6.3.2.4 ITALY
6.3.2.4.1 ITALY CANCER GENE THERAPY MARKET, BY THERAPY
6.3.2.4.1.1. ITALY GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.2.4.1.2. ITALY ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.2.4.1.3. ITALY GENE TRANSFER MARKET, BY THERAPY
6.3.2.5 SPAIN
6.3.2.5.1 SPAIN CANCER GENE THERAPY MARKET, BY THERAPY
6.3.2.5.1.1. SPAIN GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.2.5.1.2. SPAIN ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.2.5.1.3. SPAIN GENE TRANSFER MARKET, BY THERAPY
6.3.2.6 REST OF EUROPE
6.3.2.6.1 REST OF EUROPE CANCER GENE THERAPY MARKET, BY THERAPY
6.3.2.6.1.1. REST OF EUROPE GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.3.2.6.1.2. REST OF EUROPE ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.3.2.6.1.3. REST OF EUROPE GENE TRANSFER MARKET, BY THERAPY
6.4. ASIA-PACIFIC
6.4.1 ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY
6.4.1.1 ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.1.2 ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.1.3 ASIA-PACIFIC GENE TRANSFER MARKET, BY THERAPY
6.4.2 ASIA-PACIFIC CANCER GENE THERAPY, MARKET BY COUNTRY
6.4.2.1 JAPAN
6.4.2.1.1 JAPAN CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.1.1.1. JAPAN GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.1.1.2. JAPAN ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.1.1.3. JAPAN GENE TRANSFER MARKET, BY THERAPY
6.4.2.2 CHINA
6.4.2.2.1 CHINA CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.2.1.1. CHINA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.2.1.2. CHINA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.2.1.3. CHINA GENE TRANSFER MARKET, BY THERAPY
6.4.2.3 AUSTRALIA
6.4.2.3.1 AUSTRALIA CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.3.1.1. AUSTRALIA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.3.1.2. AUSTRALIA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.3.1.3. AUSTRALIA GENE TRANSFER MARKET, BY THERAPY
6.4.2.4 INDIA
6.4.2.4.1 INDIA CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.4.1.1. INDIA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.4.1.2. INDIA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.4.1.3. INDIA GENE TRANSFER MARKET, BY THERAPY
6.4.2.5 SOUTH KOREA
6.4.2.5.1 SOUTH KOREA CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.5.1.1. SOUTH KOREA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.5.1.2. SOUTH KOREA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.5.1.3. SOUTH KOREA GENE TRANSFER MARKET, BY THERAPY
6.4.2.6 TAIWAN
6.4.2.6.1 TAIWAN CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.6.1.1. TAIWAN GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.6.1.2. TAIWAN ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.6.1.3. TAIWAN GENE TRANSFER MARKET, BY THERAPY
6.4.2.7 REST OF ASIA-PACIFIC
6.4.2.7.1 REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY
6.4.2.7.1.1. REST OF ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.4.2.7.1.2. REST OF ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.4.2.7.1.3. REST OF ASIA-PACIFIC GENE TRANSFER MARKET, BY THERAPY
6.5. REST OF WORLD
6.5.1 REST OF WORLD CANCER GENE THERAPY MARKET, BY THERAPY
6.5.1.1 REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.5.1.2 REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.5.1.3 REST OF WORLD GENE TRANSFER MARKET, BY THERAPY
6.5.2 REST OF WORLD CANCER GENE THERAPY, MARKET BY COUNTRY
6.5.2.1 BRAZIL
6.5.2.1.1 BRAZIL CANCER GENE THERAPY MARKET, BY THERAPY
6.5.2.1.1.1. BRAZIL GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.5.2.1.1.2. BRAZIL ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.5.2.1.1.3. BRAZIL GENE TRANSFER MARKET, BY THERAPY
6.5.2.2 TURKEY
6.5.2.2.1 TURKEY CANCER GENE THERAPY MARKET, BY THERAPY
6.5.2.2.1.1. TURKEY GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.5.2.2.1.2. TURKEY ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.5.2.2.1.3. TURKEY GENE TRANSFER MARKET, BY THERAPY
6.5.2.3 SAUDI ARABIA
6.5.2.3.1 SAUDI ARABIA CANCER GENE THERAPY MARKET, BY THERAPY
6.5.2.3.1.1. SAUDI ARABIA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.5.2.3.1.2. SAUDI ARABIA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.5.2.3.1.3. SAUDI ARABIA GENE TRANSFER MARKET, BY THERAPY
6.5.2.4 SOUTH AFRICA
6.5.2.4.1 SOUTH AFRICA CANCER GENE THERAPY MARKET, BY THERAPY
6.5.2.4.1.1. SOUTH AFRICA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.5.2.4.1.2. SOUTH AFRICA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.5.2.4.1.3. SOUTH AFRICA GENE TRANSFER MARKET, BY THERAPY
6.5.2.5 REMAINING COUNTRIES
6.5.2.5.1 REMAINING COUNTRIES CANCER GENE THERAPY MARKET, BY THERAPY
6.5.2.5.1.1. REMAINING COUNTRIES GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY
6.5.2.5.1.2. REMAINING COUNTRIES ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY
6.5.2.5.1.3. REMAINING COUNTRIES GENE TRANSFER MARKET, BY THERAPY
7. COMPANY PROFILES
7.1. ADAPTIMMUNE
7.1.1 COMPANY OVERVIEW
7.1.2 COMPANY SNAPSHOT
7.1.3 OPERATING BUSINESS SEGMENTS
7.1.4 PRODUCT PORTFOLIO
7.1.5 BUSINESS PERFORMANCE
7.1.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.2. GLAXOSMITHKLINE
7.2.1 COMPANY OVERVIEW
7.2.2 COMPANY SNAPSHOT
7.2.3 OPERATING BUSINESS SEGMENTS
7.2.4 PRODUCT PORTFOLIO
7.2.5 BUSINESS PERFORMANCE
7.2.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.3. BLUEBIRD BIO, INC.
7.3.1 COMPANY OVERVIEW
7.3.2 COMPANY SNAPSHOT
7.3.3 OPERATING BUSINESS SEGMENTS
7.3.4 PRODUCT PORTFOLIO
7.3.5 BUSINESS PERFORMANCE
7.3.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.4. MERCK
7.4.1 COMPANY OVERVIEW
7.4.2 COMPANY SNAPSHOT
7.4.3 OPERATING BUSINESS SEGMENTS
7.4.4 PRODUCT PORTFOLIO
7.4.5 BUSINESS PERFORMANCE
7.4.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.5. CELGENE
7.5.1 COMPANY OVERVIEW
7.5.2 COMPANY SNAPSHOT
7.5.3 OPERATING BUSINESS SEGMENTS
7.5.4 PRODUCT PORTFOLIO
7.5.5 BUSINESS PERFORMANCE
7.5.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.6. SHANGHAI SUNWAY BIOTECH
7.6.1 COMPANY OVERVIEW
7.6.2 COMPANY SNAPSHOT
7.6.3 OPERATING BUSINESS SEGMENTS
7.6.4 PRODUCT PORTFOLIO
7.6.5 BUSINESS PERFORMANCE
7.6.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.7. BIOCANCELL
7.7.1 COMPANY OVERVIEW
7.7.2 COMPANY SNAPSHOT
7.7.3 OPERATING BUSINESS SEGMENTS
7.7.4 PRODUCT PORTFOLIO
7.7.5 BUSINESS PERFORMANCE
7.7.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.8. SHENZHEN SIBIONO GENETECH
7.8.1 COMPANY OVERVIEW
7.8.2 COMPANY SNAPSHOT
7.8.3 OPERATING BUSINESS SEGMENTS
7.8.4 PRODUCT PORTFOLIO
7.8.5 BUSINESS PERFORMANCE
7.8.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.9. SYNERGENE THERAPEUTICS
7.9.1 COMPANY OVERVIEW
7.9.2 COMPANY SNAPSHOT
7.9.3 OPERATING BUSINESS SEGMENTS
7.9.4 PRODUCT PORTFOLIO
7.9.5 BUSINESS PERFORMANCE
7.9.6 KEY STRATEGIC MOVES AND DEVELOPMENT
7.10. ONCOGENEX PHARMACEUTICALS
7.10.1 COMPANY OVERVIEW
7.10.2 COMPANY SNAPSHOT
7.10.3 OPERATING BUSINESS SEGMENTS
7.10.4 PRODUCT PORTFOLIO
7.10.5 BUSINESS PERFORMANCE
7.10.6 KEY STRATEGIC MOVES AND DEVELOPMENT
LIST OF TABLES
TABLE 1. GLOBAL CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 2. GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 3. ADENOVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 4. NORTH AMERICA ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 5. EUROPE ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 6. ASIA-PACIFIC ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 7. REST OF WORLD ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 8. LENTIVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 9. NORTH AMERICA LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 10. EUROPE LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 11. ASIA-PACIFIC LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 12. REST OF WORLD LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 13. RETRO VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 14. NORTH AMERICA RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 15. EUROPE RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 16. ASIA-PACIFIC RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 17. REST OF WORLD RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 18. ADENO ASSOCIATED VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 19. NORTH AMERICA ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 20. EUROPE ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 21. ASIA-PACIFIC ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 22. REST OF WORLD ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 23. HERPES SIMPLEX VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 24. NORTH AMERICA HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 25. EUROPE HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 26. ASIA-PACIFIC HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 27. REST OF WORLD HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 28. ALPHA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 29. NORTH AMERICA ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 30. EUROPE ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 31. ASIA-PACIFIC ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 32. REST OF WORLD ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 33. VACCINIA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 34. NORTH AMERICA VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 35. EUROPE VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 36. ASIA-PACIFIC VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 37. REST OF WORLD VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 38. SIMIAN VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 39. NORTH AMERICA SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 40. EUROPE SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 41. ASIA-PACIFIC SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 42. REST OF WORLD SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 43. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 44. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 45. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 46. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 47. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 48. GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 49. NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 50. EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 51. ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 52. REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 53. GLOBAL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 54. DELIVERY OF CYTOKINES GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 55. NORTH AMERICA DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 56. EUROPE DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 57. ASIA-PACIFIC DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 58. REST OF WORLD DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 59. DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 60. NORTH AMERICA DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 61. EUROPE DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 62. ASIA-PACIFIC DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 63. REST OF WORLD DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 64. ONCOLYTIC VIROTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 65. NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 66. EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 67. ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 68. REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 69. GLOBAL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 70. ELECTROPORATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 71. NORTH AMERICA ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 72. EUROPE ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 73. ASIA-PACIFIC ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 74. REST OF WORLD ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 75. SONOPORTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 76. NORTH AMERICA SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 77. EUROPE SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 78. ASIA-PACIFIC SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 79. REST OF WORLD SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 80. MAGNETOFECTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 81. NORTH AMERICA MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 82. EUROPE MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 83. ASIA-PACIFIC MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 84. REST OF WORLD MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 85. GENE GUN MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 86. NORTH AMERICA GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 87. EUROPE GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 88. ASIA-PACIFIC GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 89. REST OF WORLD GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 90. GENE TRANSFER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 91. NORTH AMERICA GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 92. EUROPE GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 93. ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 94. REST OF WORLD GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
TABLE 95. GLOBAL CANCER GENE THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
TABLE 96. NORTH AMERICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 97. NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 98. NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 99. NORTH AMERICA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 100. U.S CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 101. U.S GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 102. U.S ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 103. U.S GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 104. CANADA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 105. CANADA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 106. CANADA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 107. CANADA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 108. MEXICO CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 109. MEXICO GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 110. MEXICO ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 111. MEXICO GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 112. EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 113. EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 114. EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 115. EUROPE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 116. GERMANY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 117. GERMANY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 118. GERMANY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 119. GERMANY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 120. FRANCE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 121. FRANCE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 122. FRANCE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 123. FRANCE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 124. UK CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 125. UK GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 126. UK ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 127. UK GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 128. ITALY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 129. ITALY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 130. ITALY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 131. ITALY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 132. SPAIN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 133. SPAIN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 134. SPAIN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 135. SPAIN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 136. REST OF EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 137. REST OF EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 138. REST OF EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 139. REST OF EUROPE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 140. ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 141. ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 142. ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 143. ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 144. JAPAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 145. JAPAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 146. JAPAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 147. JAPAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 148. CHINA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 149. CHINA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 150. CHINA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 151. CHINA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 152. AUSTRALIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 153. AUSTRALIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 154. AUSTRALIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 155. AUSTRALIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 156. INDIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 157. INDIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 158. INDIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 159. INDIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 160. SOUTH KOREA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 161. SOUTH KOREA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 162. SOUTH KOREA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 163. SOUTH KOREA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 164. TAIWAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 165. TAIWAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 166. TAIWAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 167. TAIWAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 168. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 169. REST OF ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 170. REST OF ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 171. REST OF ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 172. REST OF WORLD CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 173. REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 174. REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 175. REST OF WORLD GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 176. BRAZIL CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 177. BRAZIL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 178. BRAZIL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 179. BRAZIL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 180. TURKEY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 181. TURKEY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 182. TURKEY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 183. TURKEY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 184. SAUDI ARABIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 185. SAUDI ARABIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 186. SAUDI ARABIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 187. SAUDI ARABIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 188. SOUTH AFRICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 189. SOUTH AFRICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 190. SOUTH AFRICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 191. SOUTH AFRICA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 192. REMAINING COUNTRIES CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 193. REMAINING COUNTRIES GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 194. REMAINING COUNTRIES ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 195. REMAINING COUNTRIES GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
TABLE 196. ADAPTIMMUNE: COMPANY SNAPSHOT
TABLE 197. ADAPTIMMUNE: OPERATING SEGMENTS
TABLE 198. ADAPTIMMUNE: PRODUCT PORTFOLIO
TABLE 199. ADAPTIMMUNE: KEY STRATERGY
TABLE 200. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 201. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 202. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 203. GLAXOSMITHKLINE: KEY STRATERGY
TABLE 204. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE 205. BLUEBIRD BIO, INC.: OPERATING SEGMENTS
TABLE 206. BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
TABLE 207. BLUEBIRD BIO, INC.: KEY STRATERGY
TABLE 208. MERCK: COMPANY SNAPSHOT
TABLE 209. MERCK: OPERATING SEGMENTS
TABLE 210. MERCK: PRODUCT PORTFOLIO
TABLE 211. MERCK: KEY STRATERGY
TABLE 212. CELGENE: COMPANY SNAPSHOT
TABLE 213. CELGENE: OPERATING SEGMENTS
TABLE 214. CELGENE: PRODUCT PORTFOLIO
TABLE 215. CELGENE: KEY STRATERGY
TABLE 216. SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
TABLE 217. SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
TABLE 218. SHANGHAI SUNWAY BIOTECH: PRODUCT PORTFOLIO
TABLE 219. SHANGHAI SUNWAY BIOTECH: KEY STRATERGY
TABLE 220. BIOCANCELL: COMPANY SNAPSHOT
TABLE 221. BIOCANCELL: OPERATING SEGMENTS
TABLE 222. BIOCANCELL: PRODUCT PORTFOLIO
TABLE 223. BIOCANCELL: KEY STRATERGY
TABLE 224. SHENZHEN SIBIONO GENETECH: COMPANY SNAPSHOT
TABLE 225. SHENZHEN SIBIONO GENETECH: OPERATING SEGMENTS
TABLE 226. SHENZHEN SIBIONO GENETECH: PRODUCT PORTFOLIO
TABLE 227. SHENZHEN SIBIONO GENETECH: KEY STRATERGY
TABLE 228. SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 229. SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
TABLE 230. SYNERGENE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 231. SYNERGENE THERAPEUTICS: KEY STRATERGY
TABLE 232. ONCOGENEX PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 233. ONCOGENEX PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 234. ONCOGENEX PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 235. ONCOGENEX PHARMACEUTICALS: KEY STRATERGY
LIST OF FIGURES
FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 2. GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 3. ADENOVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 4. NORTH AMERICA ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 5. EUROPE ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 6. ASIA-PACIFIC ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 7. REST OF WORLD ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 8. LENTIVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 9. NORTH AMERICA LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 10. EUROPE LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 11. ASIA-PACIFIC LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 12. REST OF WORLD LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 13. RETRO VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 14. NORTH AMERICA RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 15. EUROPE RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 16. ASIA-PACIFIC RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 17. REST OF WORLD RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 18. ADENO ASSOCIATED VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 19. NORTH AMERICA ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 20. EUROPE ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 21. ASIA-PACIFIC ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 22. REST OF WORLD ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 23. HERPES SIMPLEX VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 24. NORTH AMERICA HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 25. EUROPE HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 26. ASIA-PACIFIC HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 27. REST OF WORLD HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 28. ALPHA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 29. NORTH AMERICA ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 30. EUROPE ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 31. ASIA-PACIFIC ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 32. REST OF WORLD ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 33. VACCINIA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 34. NORTH AMERICA VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 35. EUROPE VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 36. ASIA-PACIFIC VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 37. REST OF WORLD VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 38. SIMIAN VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 39. NORTH AMERICA SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 40. EUROPE SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 41. ASIA-PACIFIC SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 42. REST OF WORLD SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 43. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 44. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 45. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 46. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 47. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 48. GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 49. NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 50. EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 51. ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 52. REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 53. GLOBAL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 54. DELIVERY OF CYTOKINES GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 55. NORTH AMERICA DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 56. EUROPE DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 57. ASIA-PACIFIC DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 58. REST OF WORLD DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 59. DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 60. NORTH AMERICA DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 61. EUROPE DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 62. ASIA-PACIFIC DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 63. REST OF WORLD DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 64. ONCOLYTIC VIROTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 65. NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 66. EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 67. ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 68. REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 69. GLOBAL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 70. ELECTROPORATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 71. NORTH AMERICA ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 72. EUROPE ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 73. ASIA-PACIFIC ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 74. REST OF WORLD ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 75. SONOPORTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 76. NORTH AMERICA SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 77. EUROPE SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 78. ASIA-PACIFIC SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 79. REST OF WORLD SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 80. MAGNETOFECTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 81. NORTH AMERICA MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 82. EUROPE MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 83. ASIA-PACIFIC MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 84. REST OF WORLD MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 85. GENE GUN MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 86. NORTH AMERICA GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 87. EUROPE GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 88. ASIA-PACIFIC GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 89. REST OF WORLD GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 90. GENE TRANSFER MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 91. NORTH AMERICA GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 92. EUROPE GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 93. ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 94. REST OF WORLD GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 95. GLOBAL CANCER GENE THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD
FIGURE 96. NORTH AMERICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 97. NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 98. NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 99. NORTH AMERICA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 100. U.S CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 101. U.S GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 102. U.S ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 103. U.S GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 104. CANADA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 105. CANADA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 106. CANADA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 107. CANADA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 108. MEXICO CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 109. MEXICO GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 110. MEXICO ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 111. MEXICO GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 112. EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 113. EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 114. EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 115. EUROPE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 116. GERMANY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 117. GERMANY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 118. GERMANY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 119. GERMANY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 120. FRANCE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 121. FRANCE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 122. FRANCE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 123. FRANCE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 124. UK CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 125. UK GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 126. UK ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 127. UK GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 128. ITALY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 129. ITALY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 130. ITALY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 131. ITALY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 132. SPAIN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 133. SPAIN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 134. SPAIN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 135. SPAIN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 136. REST OF EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 137. REST OF EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 138. REST OF EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 139. REST OF EUROPE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 140. ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 141. ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 142. ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 143. ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 144. JAPAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 145. JAPAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 146. JAPAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 147. JAPAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 148. CHINA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 149. CHINA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 150. CHINA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 151. CHINA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 152. AUSTRALIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 153. AUSTRALIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 154. AUSTRALIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 155. AUSTRALIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 156. INDIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 157. INDIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 158. INDIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 159. INDIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 160. SOUTH KOREA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 161. SOUTH KOREA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 162. SOUTH KOREA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 163. SOUTH KOREA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 164. TAIWAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 165. TAIWAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 166. TAIWAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 167. TAIWAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 168. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 169. REST OF ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 170. REST OF ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 171. REST OF ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 172. REST OF WORLD CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 173. REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 174. REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 175. REST OF WORLD GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 176. BRAZIL CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 177. BRAZIL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 178. BRAZIL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 179. BRAZIL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 180. TURKEY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 181. TURKEY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 182. TURKEY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 183. TURKEY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 184. SAUDI ARABIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 185. SAUDI ARABIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 186. SAUDI ARABIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 187. SAUDI ARABIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 188. SOUTH AFRICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 189. SOUTH AFRICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 190. SOUTH AFRICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 191. SOUTH AFRICA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 192. REMAINING COUNTRIES CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 193. REMAINING COUNTRIES GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 194. REMAINING COUNTRIES ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 195. REMAINING COUNTRIES GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD
FIGURE 196. ADAPTIMMUNE: NET SALES,2017-2022
FIGURE 197. GLAXOSMITHKLINE: NET SALES,2017-2022
FIGURE 198. BLUEBIRD BIO, INC.: NET SALES,2017-2022
FIGURE 199. MERCK: NET SALES,2017-2022
FIGURE 200. CELGENE: NET SALES,2017-2022
FIGURE 201. SHANGHAI SUNWAY BIOTECH: NET SALES,2017-2022
FIGURE 202. BIOCANCELL: NET SALES,2017-2022
FIGURE 203. SHENZHEN SIBIONO GENETECH: NET SALES,2017-2022
FIGURE 204. SYNERGENE THERAPEUTICS: NET SALES,2017-2022
FIGURE 205. ONCOGENEX PHARMACEUTICALS: NET SALES,2017-2022